Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pediatric Hematology/Oncology
•
Rheumatology
•
Hematology
•
Pediatric Hematology
•
Cyclophosphamide
•
General Rheumatology
•
Neutropenia
When would you consider using G-CSF in patients with rheumatic disease who have received cyclophosphamide?
Related Questions
What is your approach to management of chronic neutropenia in a patient with Sjogren’s who was recently diagnosed with metastatic endometrial cancer and plans to start chemotherapy?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?
Is there a concern for the potential of future congenital malformations in offspring when preservation of eggs and sperm is done AFTER cyclophosphamide treatment given that it is an alkylating agent?
For patients with suspected complement-mediated TMA, are there specific clinical or laboratory parameters that can help guide the decision for starting empirical treatment (e.g., eculizumab) while awaiting the results of complement testing?
Are SCDs contraindicated in patients with acute DVTs?
Is there any indication for hydroxyurea in patients with sickle cell trait?
What additional testing is recommended with heterozygous HFE C282Y mutation whose ferritin is elevated and transferrin saturation percentage is at baseline?
In a young female with severe osteoporosis due to congenital estrogen deficiency, can estrogen be prescribed if genetic testing for congenital disorders reveals a heterozygous Factor V Leiden mutation?
What is your approach to DVT prophylaxis in patients who require IVIG but are at increased risk for thrombotic events?